SEED Therapeutics Wins 2026 Prix Galien USA Best Start-Up
SEED Therapeutics wins 2026 Prix Galien USA 'Best Start-Up' Award, marking second consecutive nomination.
August 17, 2026
1 min read
43 views
Source: manilatimes.net
SEED Therapeutics has been named the winner of the 2026 Prix Galien USA "Best Start-Up" Award, marking its second consecutive nomination for the honor. The award recognizes the company's progress in rational molecular glue development and targeted protein degradation.
The recognition follows the first-in-human proof of mechanism for its lead RBM39 degrader, ST-01156, in an ongoing Phase 1 study. This milestone demonstrates the potential of SEED's platform to address challenging disease targets.
SEED Therapeutics is a clinical-stage biotech company focused on developing molecular glue degraders. The Prix Galien USA is one of the most prestigious awards in the biopharmaceutical industry, honoring innovative drug development.
ā Frequently Asked Questions
What is the Prix Galien USA?
The Prix Galien USA is a prestigious award in the biopharmaceutical industry, recognizing innovative drug development and medical technologies.
What is SEED Therapeutics' lead drug candidate?
SEED's lead candidate is ST-01156, an RBM39 degrader that has shown proof of mechanism in a Phase 1 study.
What is molecular glue degradation?
Molecular glue degraders are small molecules that induce targeted protein degradation by bringing a target protein into proximity with an E3 ligase, leading to its ubiquitination and destruction.
